Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Circulation Journal

• Publication date

  2010-05-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1253/CIRCJ.CJ-10-0109PMID 20501957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia.

  2010cited by this paper
• The Therapeutic Potential of Erythropoiesis-Stimulating Agents for Tissue Protection: A Tale of Two Receptors

  2010cited by this paper
• Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency.

  2009cited by this paper
• Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention.

  2009cited by this paper
• Why do we still not have cardioprotective drugs?

  2009cited by this paper
• Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI-II registry

  2008cited by this paper
• Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III).

  2008cited by this paper
• Lack of additional benefit of intracoronary transplantation of autologous peripheral blood stem cell in patients with acute myocardial infarction.

  2007cited by this paper
• Erythropoietin Attenuates the Development of Experimental Autoimmune Myocarditis

  2007cited by this paper
• Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy

  2006cited by this paper
• Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis.

  2006cited by this paper
• Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs.

  2006cited by this paper
• Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study.

  2006cited by this paper
• A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study

  2006cited by this paper
• Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony–Stimulating Factor (FIRSTLINE-AMI)

  2005cited by this paper
• Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers.

  2005cited by this paper
• High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention.

  2005cited by this paper
• Mechanisms of erythropoietin‐mediated cardioprotection during ischemia‐reperfusion injury: role of protein kinase C and phosphatidylinositol 3‐kinase signaling

  2005cited by this paper
• Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction: The CAPRICORN Echo Substudy

  2004cited by this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers

  2004cited by this paper
• Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injury

  2004cited by this paper
• Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

  2003cited by this paper
• A novel protective effect of erythropoietin in the infarcted heart.

  2003cited by this paper
• Erythropoietin improves cardiac contractility in post‐hypoxic mice

  2003cited by this paper
• Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

  2002cited by this paper
• Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

  2002cited by this paper
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  2002cited by this paper
• Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.

  1991cited by this paper

• Association of endogenous erythropoietin with 10-year risk of all-cause and cardiovascular mortality.

  2025cites this paper
• Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials

  2022influential citation
• Application of Erythropoietin in Chronic Heart Failure Treatment.

  2020cites this paper
• Effects of Epoetin Alfa in STEMI patients Long term effects of Epoetin Alfa in patients with ST- elevation myocardial infarction

  2019cites this paper
• Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II)　- A Randomized Controlled Clinical Trial.

  2018cites this paper
• Effect of Erythropoietin Administration on Myocardial Viability and Coronary Microvascular Dysfunction in Anterior Acute Myocardial Infarction: Randomized Controlled Trial in the Japanese Population

  2018cites this paper
• Harms of off-label erythropoiesis-stimulating agents for critically ill people.

  2017cites this paper
• Erythropoiesis-stimulating Agents in Critically Ill Trauma Patients: A Systematic Review and Meta-analysis

  2017cites this paper
• Comparative analysis of tissue expression and methylation reveals the crucial hypoxia genes in hypoxia-resistant animals

  2017influential citation
• The use of pharmacological conditioning strategies to improve donor heart preservation in cardiac transplantation

  2016cites this paper
• Priming with erythropoietin enhances cell survival and angiogenic effect of mesenchymal stem cell implantation in rat limb ischemia

  2016cites this paper
• Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.

  2015cites this paper
• Administration of erythropoietin in patients with myocardial infarction: does it make sense? An updated and comprehensive meta-analysis and systematic review.

  2015cites this paper
• Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery: reducing risk of heart failure patients in noncardiac surgery.

  2015cites this paper
• Message From the Editor-in-Chief.

  2015cites this paper
• High‐dose erythropoietin for tissue protection

  2014cites this paper
• Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data.

  2014cites this paper
• Die Wirkung von Erythropoietin auf die Thrombozytenfunktion im akuten Myokardinfarkt

  2014cites this paper
• Effects of Intraosseous Erythropoietin during Hemorrhagic Shock in Swine

  2014cites this paper
• Pharmacologic Therapy That Simulates Conditioning for Cardiac Ischemic/Reperfusion Injury

  2014cites this paper
• Erythropoietin and the heart: physiological effects and the therapeutic perspective.

  2014influential citation
• Effect of erythropoietin loading chitosan-tripolyphosphate nanoparticles on an IgA nephropathy rat model

  2014cites this paper
• Erythropoietin and Protection of Renal Function in Cardiac Surgery (the EPRICS Trial)

  2014cites this paper
• Longitudinal Assessments of Erythropoietin-Stimulating Agent Responsiveness and the Association with Specific Clinical Outcomes in Dialysis Patients

  2014cites this paper
• High-Dose Erythropoietin in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Outcome after percutaneous coronary intervention

  2013cites this paper
• What is the Role of Erythropoietin in Acute Myocardial Infarct? Bridging the Gap Between Experimental Models and Clinical Trials

  2013cites this paper
• Myocardial infarction: cardioprotection by erythropoietin.

  2013cites this paper
• Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion

  2013cites this paper
• Asialoerythropoietin Exerts Stronger Angiogenic Activity than Erythropoietin Via its Binding Affinity to Tissue

  2013cites this paper
• Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction

  2013cites this paper
• High-dose erythropoietin during cardiac resuscitation lessens postresuscitation myocardial stunning in swine.

  2013cites this paper
• The neuroprotective mechanism of erythropoietin-TAT fusion protein against neurodegeneration from ischemic brain injury.

  2013cites this paper
• Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial.

  2013cites this paper
• Erythropoietin in cardiac disease: effective or harmful?

  2013cites this paper
• Erythropoietin and the vascular wall: the controversy continues.

  2013cites this paper
• Effects of erythropoietin administration on iron status in patients with ST-elevation myocardial infarction who underwent successful percutaneous coronary intervention.

  2013cites this paper
• Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction.

  2013cites this paper
• A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'.

  2013cites this paper
• Effects of Erythropoietin on Blood Vessels and the Heart

  2013cites this paper
• Support Clinical Studies Based on The Ethical Guideline for Clinical Study

  2013cites this paper
• Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

  2012cites this paper
• A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans

  2012cites this paper
• Erythropoietin Improves Long-Term Outcomes in Patients with Acute Kidney Injury after Coronary Artery Bypass Grafting

  2012cites this paper
• Novel treatment strategies

  2012cites this paper
• Did Clinical Trials in Which Erythropoietin Failed to Reduce Acute Myocardial Infarct Size Miss a Narrow Therapeutic Window?

  2012cites this paper
• Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning

  2012cites this paper
• An increase in endogenous erythropoietin concentrations has no cardioprotective effects in patients undergoing coronary artery bypass graft surgery.

  2012cites this paper
• Cardioprotection from ischemia/reperfusion injury: basic and translational research.

  2012cites this paper
• Design and Rationale of Low-Dose Erythropoietin in Patients with ST-Segment Elevation Myocardial Infarction (EPO-AMI-II Study): A Randomized Controlled Clinical Trial

  2012influential citation
• Erythropoietin, progenitor cells and restenosis. A critique of Stein et al.

  2012cites this paper
• Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials.

  2012cites this paper
• Quelles potentialités thérapeutiques pour l’érythropoiétine recombinante dans le traitement des traumatismes du système nerveux central ?

  2012cites this paper
• Left ventricular functional assessment in murine models of ischemic and dilated cardiomyopathy using [18 F]FDG-PET: comparison with cardiac MRI and monitoring erythropoietin therapy

  2012cites this paper
• Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.

  2012cites this paper
• Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy

  2012cites this paper
• Conditioning the heart to prevent myocardial reperfusion injury during PPCI

  2012cites this paper
• Intraosseous Erythropoietin for Acute Tissue Protection in Battlefield Casualties Suffering Hypovolemic Shock

  2012cites this paper
• Nonviral gene delivery of erythropoietin by mesenchymal stromal cells

  2011cites this paper
• Endogenous serum erythropoietin and no‐reflow in patients with ST‐elevation myocardial infarction

  2011cites this paper
• The therapeutic potential of ischemic conditioning: an update

  2011cites this paper
• Erythropoietin as a cardioprotective agent: down but not out

  2011cites this paper
• Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond

  2011cites this paper
• [Clinical study from Japan and its reflections: evaluation of the prospective observation of erythropoietin--administration for the treatment of acute myocardial infarction (EPO/AMI-1) study].

  2011cites this paper
• Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review

  2011cites this paper
• Intervention With an Erythropoietin-Derived Peptide Protects Against Neuroglial and Vascular Degeneration During Diabetic Retinopathy

  2011cites this paper
• Agentes estimulantes de la eritropoyesis en la enfermedad renal crónica

  2011cites this paper
• Erythropoietin in the intensive care unit: beyond treatment of anemia

  2011cites this paper
• Targeting the reperfusion injury salvage kinase pathway in the clinical setting

  2011cites this paper
• Kardiorenales Anämiesyndrom – Was ist das?

  2011cites this paper
• Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction

  2011cites this paper
• Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial

  2011cites this paper
• Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.

  2011cites this paper
• Effects of erythropoietin on angiogenesis after myocardial infarction in porcine

  2011cites this paper
• EPO's rescue mission in acute myocardial infarction: still more hopes than evidence.

  2010cites this paper
• Still searching for a new therapeutic strategy for acute myocardial infarction.

  2010cites this paper
• A novel program to accurately quantify infarction volume by (99m)Tc MIBI SPECT, and its application for re-analyzing the effect of erythropoietin administration in patients with acute myocardial infarction.

  2010cites this paper
• Erythropoietin enhances hydrogen peroxide-mediated dilatation of canine coronary collateral arterioles during myocardial ischemia in dogs in vivo.

  2010cites this paper
• HEARTJNL223867 1560..1565

  year unknowncites this paper
• Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial

  year unknowncites this paper